Model Teaches Skin Lesion Diagnosis and Removal

Publication
Article
Oncology NEWS InternationalOncology NEWS International Vol 7 No 9
Volume 7
Issue 9

BRISTOL, UK--A life-size model of a face with the look, feel, and color of real tissue allows medical students to recognize a wide variety of skin lesions--basal cell carcinomas, malignant melanomas, cysts, and warts--and practice a number of procedures, including lesion removal and planning of incisions.

BRISTOL, UK--A life-size model of a face with the look, feel, and color of real tissue allows medical students to recognize a wide variety of skin lesions--basal cell carcinomas, malignant melanomas, cysts, and warts--and practice a number of procedures, including lesion removal and planning of incisions.

The face is one of a line of soft-tissue simulators produced by Limbs and Things Limited. The company’s first product was a heart model designed to demonstrate atrial septal defect, including a patch that can be stitched on to the defect and removed, allowing for re-use of the simulator. Other models for use in minor surgery workshops include an ingrown toenail simulator and an intramuscular pad for practicing injections.

Limbs and Things Limited can be reached at Radnor Business Centre, Radnor Road, Horfield, Bristol, UK BS7 8QS. Telephone: +44 117 944 6466; fax: +44 117 994 6222.

Newsletter

Stay up to date on recent advances in the multidisciplinary approach to cancer.

Recent Videos
5 experts are featured in this series
5 experts are featured in this series
2 experts in this video
“If you have a [patient in the] fourth or fifth line, [JNJ-5322] could be a valid drug of choice,” said Rakesh Popat, BSc, MBBS, MRCP, FRCPath, PhD.
2 experts in this video
Earlier treatment with daratumumab may be better tolerated for patients with pretreated MRD-negative multiple myeloma.
The trispecific antibody JNJ-5322 demonstrated superior efficacy vs approved agents in multiple myeloma in results shared at the 2025 EHA Congress.
Despite CD19 CAR T-cell therapy exhibiting efficacy in patients with relapsed/refractory large B-cell lymphoma, less than half achieve long-term remission.
4 experts in this video
4 experts in this video
Related Content